Royal London Asset Management Ltd. Acquires 19,095 Shares of Hologic, Inc. (NASDAQ:HOLX)

Royal London Asset Management Ltd. increased its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 6.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 335,011 shares of the medical equipment provider's stock after acquiring an additional 19,095 shares during the period. Royal London Asset Management Ltd. owned about 0.14% of Hologic worth $27,290,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Cetera Investment Advisers grew its stake in Hologic by 188.9% in the first quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider's stock valued at $1,595,000 after purchasing an additional 13,380 shares in the last quarter. Cetera Advisors LLC grew its stake in shares of Hologic by 144.8% in the 1st quarter. Cetera Advisors LLC now owns 8,800 shares of the medical equipment provider's stock valued at $686,000 after buying an additional 5,205 shares in the last quarter. CWM LLC increased its holdings in Hologic by 4.1% in the second quarter. CWM LLC now owns 9,638 shares of the medical equipment provider's stock worth $716,000 after buying an additional 382 shares during the last quarter. QRG Capital Management Inc. raised its position in Hologic by 16.8% during the second quarter. QRG Capital Management Inc. now owns 89,162 shares of the medical equipment provider's stock valued at $6,620,000 after acquiring an additional 12,845 shares in the last quarter. Finally, SG Americas Securities LLC lifted its stake in Hologic by 583.1% in the second quarter. SG Americas Securities LLC now owns 229,171 shares of the medical equipment provider's stock valued at $17,016,000 after acquiring an additional 195,623 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently commented on HOLX. Citigroup lowered Hologic from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Raymond James upped their price objective on shares of Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a report on Tuesday, November 5th. Mizuho dropped their target price on shares of Hologic from $90.00 to $87.00 and set an "outperform" rating on the stock in a report on Tuesday, November 5th. Leerink Partners lowered their price target on Hologic from $95.00 to $90.00 and set an "outperform" rating on the stock in a research report on Tuesday, October 8th. Finally, Needham & Company LLC reissued a "buy" rating and set a $90.00 price objective on shares of Hologic in a research report on Tuesday, October 15th. Four analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $89.91.

Hologic Price Performance

Hologic stock traded down $0.66 during mid-day trading on Friday, hitting $75.34. 1,356,780 shares of the company were exchanged, compared to its average volume of 1,560,994. Hologic, Inc. has a 1-year low of $67.59 and a 1-year high of $84.67. The company has a quick ratio of 3.03, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The business has a fifty day moving average of $79.81 and a 200 day moving average of $78.52. The company has a market capitalization of $17.10 billion, a PE ratio of 22.62, a price-to-earnings-growth ratio of 2.42 and a beta of 0.96.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting the consensus estimate of $1.01. The business had revenue of $987.90 million for the quarter, compared to the consensus estimate of $978.25 million. Hologic had a return on equity of 19.79% and a net margin of 19.59%. Hologic's revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.89 EPS. As a group, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Buying and Selling at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the business's stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares of the company's stock, valued at $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 1.75% of the company's stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.